DENTSPLY SIRONA (NASDAQ:XRAY) Updates FY 2026 Earnings Guidance

DENTSPLY SIRONA (NASDAQ:XRAY) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 1.400-1.500 for the period, compared to the consensus earnings per share estimate of 1.430. The company issued revenue guidance of $3.5 billion-$3.6 billion, compared to the consensus revenue estimate of $3.6 billion.

DENTSPLY SIRONA Stock Down 2.9%

Shares of XRAY stock traded down $0.33 during trading hours on Wednesday, reaching $11.04. The company had a trading volume of 4,258,528 shares, compared to its average volume of 4,469,461. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.03 and a current ratio of 1.51. DENTSPLY SIRONA has a twelve month low of $9.85 and a twelve month high of $17.18. The company has a market capitalization of $2.21 billion, a P/E ratio of -3.68, a price-to-earnings-growth ratio of 1.32 and a beta of 0.93. The stock’s fifty day simple moving average is $12.14 and its 200 day simple moving average is $12.02.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The company had revenue of $880.00 million during the quarter, compared to analyst estimates of $841.80 million. During the same quarter last year, the business posted $0.43 EPS. DENTSPLY SIRONA’s quarterly revenue was up .1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, sell-side analysts expect that DENTSPLY SIRONA will post 1.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Wells Fargo & Company raised their price objective on DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a research note on Monday, April 20th. UBS Group lowered their price objective on DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Robert W. Baird raised their price objective on DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a research note on Friday, February 27th. Finally, Citigroup assumed coverage on DENTSPLY SIRONA in a research note on Wednesday, April 15th. They set a “sell” rating and a $10.00 price objective for the company. Three equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $13.73.

Insider Activity at DENTSPLY SIRONA

In other news, Director James D. Forbes bought 5,000 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was bought at an average price of $12.48 per share, for a total transaction of $62,400.00. Following the transaction, the director owned 10,000 shares in the company, valued at $124,800. The trade was a 100.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gregory T. Lucier bought 27,555 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was purchased at an average price of $14.24 per share, with a total value of $392,383.20. Following the transaction, the director owned 27,555 shares in the company, valued at approximately $392,383.20. This represents a ? increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders bought 70,000 shares of company stock valued at $956,437. Insiders own 0.52% of the company’s stock.

More DENTSPLY SIRONA News

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Revenue beat and underlying adjusted profitability: Q1 revenue came in at $880M versus the ~$842M consensus, and the company reported adjusted gross margin of 50.7% and adjusted EBITDA margin of 14.7%, indicating operational progress despite GAAP noise. Dentsply Sirona beats Q1 sales expectations (MSN)
• Positive Sentiment: New product and tech momentum: Launched Smart View?Detect (FDA?cleared AI diagnostic aid) and continues to expand connected?technology distribution — product innovation and distributor deals could support mid?term growth in higher?margin digital offerings. Smart View?Detect launch (Business Insider)
• Positive Sentiment: U.S. distribution expansion: Enhanced agreement with Atlanta Dental Supply broadens U.S. reach for its connected solutions, which may help drive adoption of higher?value systems (e.g., CEREC) over time. Atlanta Dental Supply distribution deal (GlobeNewswire)
• Neutral Sentiment: FY?2026 guidance reiterated but conservative vs. some estimates: Company set adjusted EPS guidance of $1.40–$1.50 (street ~$1.43) and revenue around $3.5–$3.6B; guidance is in line with management’s turnaround plan but leaves little upside. Q1 press release / guidance (Dentsply Sirona slides)
• Neutral Sentiment: Earnings call/transcript available for detail: Management commentary in the Q1 call will be key for how management plans to stabilize U.S. demand, manage tariffs and continue debt reduction. Q1 2026 earnings call transcript (Seeking Alpha)
• Negative Sentiment: EPS miss and YoY earnings decline: Reported adjusted EPS of $0.27 missed the ~$0.28 consensus by $0.01 and is down from $0.43 a year ago — a signal that profitability recovery is still early. Q1 EPS missed estimates (Zacks)
• Negative Sentiment: Analyst downtick: Mizuho cut its price target from $16 to $14 and moved to Neutral, reducing near?term upside expectations and likely contributing to downward pressure on the stock. Mizuho price target cut (Benzinga)
• Negative Sentiment: Street consensus and sentiment remain cautious: Broker consensus is generally a Hold; GAAP net loss and negative net margin highlight that headline profitability and cash conversion remain risk factors. Average recommendation Hold (American Banking News)

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in XRAY. AQR Capital Management LLC lifted its holdings in shares of DENTSPLY SIRONA by 109.8% in the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after purchasing an additional 6,970,086 shares during the last quarter. Armistice Capital LLC lifted its holdings in shares of DENTSPLY SIRONA by 1,044.0% in the 3rd quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock worth $72,790,000 after purchasing an additional 5,234,587 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in shares of DENTSPLY SIRONA by 662.0% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock worth $58,480,000 after purchasing an additional 4,003,606 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of DENTSPLY SIRONA by 827.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after purchasing an additional 2,172,343 shares during the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of DENTSPLY SIRONA by 1,032.5% in the 4th quarter. Marshall Wace LLP now owns 2,236,786 shares of the medical instruments supplier’s stock worth $25,566,000 after purchasing an additional 2,039,280 shares during the last quarter. Institutional investors and hedge funds own 95.70% of the company’s stock.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.